Table 1 Characteristics of the study population (A) and clinical data of Juvenile Idiopathic Arthritis patients (B)

(A) Study population

JIA

HC

 Number of samples

14

10

 Numbers of male (%)/

 female (%)

6 (42.9%)/

8 (57.1%)

2 (20%)/

8 (80%)

 Age at time of inclusion (years)

16.1 ± 5.0 (16; 8–27)

23.4 ± 1.69 (23.5; 19–25)

 Age at time of diagnosis (years)

5 ± 4.1 (3.5; 1–15)

-

 Disease duration (years)

11.1 ± 6.0 (12.5; 1–24)

-

(B) Clinical Data in JIA

 Medication

13/92.9%

 Nonsteroidal anti-inflammatory drug (in therapeutic dosages)

7/50%

 Methotrexate (at < 15 mg/m²/week)

7/50%

 Glucocorticoids (at < 0.1 mg/kg/d)

3/21.4%

 Biologicals (in therapeutic dosages)

10/71.4%

Tocilizumab 1/7.1%

Adalimumab 4/28.6%

Abatacept 2/14.3%

Etanercept 3/21.4%

 Mycophenolate Mofetil

2/14.3%

 Antinuclear antibodies positive

11/78.6%

 Rheumatoid factor positive

0/0%

 C-reactive protein (mg/dl)

0.2 ± 0.3 (0.0; 0–0.9)

 Erythrocyte sedimentation rate (mm/h)

11.7 ± 10.7 (6.5; 2–35)

 Leukocytes (× 10³ per μl)

7.0 ± 2.3 (6.7; 2.4–11.5)

 Lymphocytes (G/l)

2.6 ± 0.8 (2.6; 1.3–4.3)

 Lymphocytes (%)

39.9 ± 10.6 (39.5; 13.8–64)

 Thrombocytes (× 10³ per μl)

231.3 ± 54.6 (232; 138–327)

 Immunoglobulin G (mg/dl)

912.9 ± 353.1 (992; 133–1309)

 Active joints

4/28.5%

ACR active joints if positive: 1; 3; 3; 4